Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management

Objective

To review data regarding the epidemiology, pathophysiology, characteristics, and management of COVID-19–associated headache. The persistence of headache after the acute phase of COVID-19 was also reviewed.

Activity Disclosures 

No commercial support has been accepted related to the development or publication of this activity.

Debbie L. Hay has been a consultant or speaker for Lilly, Amgen, Teva, Intarcia, Merck Sharp & Dohme, and has received research funding from Living Cell Technologies in the past 3 years. This activity underwent peer review in line with standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Accreditation
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 1 hour. To successfully earn credit, participants must access and complete the activity during the valid credit period, which is up to two years from initial publication. Additionally, up to 3 attempts and a score of 70% or better is needed to pass the post test.